## Antonio Vena

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2728770/publications.pdf Version: 2024-02-01

		44042	25770
181	12,795	48	108
papers	citations	h-index	g-index
183 all docs	183 docs citations	183 times ranked	13352 citing authors

#	Article	IF	CITATIONS
1	Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clinical Infectious Diseases, 2008, 46, 1813-1821.	2.9	4,375
2	How to manage Pseudomonas aeruginosa infections. Drugs in Context, 2018, 7, 1-18.	1.0	491
3	Infections Due to Scedosporium apiospermum and Scedosporium prolificans in Transplant Recipients: Clinical Characteristics and Impact of Antifungal Agent Therapy on Outcome. Clinical Infectious Diseases, 2005, 40, 89-99.	2.9	409
4	The novel Chinese coronavirus (2019â€nCoV) infections: Challenges for fighting the storm. European Journal of Clinical Investigation, 2020, 50, e13209.	1.7	285
5	Trends in Risk Profiles for and Mortality Associated with Invasive Aspergillosis among Liver Transplant Recipients. Clinical Infectious Diseases, 2003, 36, 46-52.	2.9	228
6	Treatment of Infections Due to MDR Gram-Negative Bacteria. Frontiers in Medicine, 2019, 6, 74.	1.2	211
7	Bloodstream infections in critically ill patients with COVIDâ€19. European Journal of Clinical Investigation, 2020, 50, e13319.	1.7	203
8	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Medicine, 2013, 39, 2092-2106.	3.9	169
9	A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality. Intensive Care Medicine, 2015, 41, 1601-1610.	3.9	165
10	Pulmonary Cryptococcosis in Solid Organ Transplant Recipients: Clinical Relevance of Serum Cryptococcal Antigen. Clinical Infectious Diseases, 2008, 46, e12-e18.	2.9	163
11	Epidemiology of candidemia in intensive care units. International Journal of Antimicrobial Agents, 2008, 32, S87-S91.	1.1	161
12	Molecular Diagnosis of Infective Endocarditis by Real-Time Broad-Range Polymerase Chain Reaction (PCR) and Sequencing Directly From Heart Valve Tissue. Medicine (United States), 2007, 86, 195-202.	0.4	151
13	The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory support and cardiothoracic organ transplant recipients: Executive summary. Journal of Heart and Lung Transplantation, 2016, 35, 261-282.	0.3	149
14	Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients—a multinational observational study by the European Confederation of Medical Mycology. Clinical Microbiology and Infection, 2022, 28, 580-587.	2.8	133
15	Current Epidemiology and Outcome of Infective Endocarditis. Medicine (United States), 2015, 94, e1816.	0.4	129
16	Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. Respiratory Physiology and Neurobiology, 2020, 279, 103455.	0.7	129
17	Dalbavancin in the treatment of different gram-positive infections: a real-life experience. International Journal of Antimicrobial Agents, 2018, 51, 571-577.	1.1	125
18	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	2.5	123

#	Article	IF	CITATIONS
19	Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience. International Journal of Antimicrobial Agents, 2019, 53, 408-415.	1.1	120
20	Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. PLoS ONE, 2017, 12, e0179136.	1.1	115
21	Risk Factors of Invasive Aspergillosis after Heart Transplantation: Protective Role of Oral Itraconazole Prophylaxis. American Journal of Transplantation, 2004, 4, 636-643.	2.6	110
22	Valve surgery in active infective endocarditis: A simple score to predict in-hospital prognosis. International Journal of Cardiology, 2014, 175, 133-137.	0.8	105
23	Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis. Clinical Infectious Diseases, 2014, 58, 1413-1421.	2.9	104
24	Evaluation of antifungal use in a tertiary care institution: antifungal stewardship urgently needed. Journal of Antimicrobial Chemotherapy, 2014, 69, 1993-1999.	1.3	101
25	Prophylaxis With Caspofungin for Invasive Fungal Infections in High-Risk Liver Transplant Recipients. Transplantation, 2009, 87, 424-435.	0.5	99
26	Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Current Opinion in Critical Care, 2018, 24, 385-393.	1.6	95
27	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 555.	1.0	93
28	Impact of Zygomycosis on Microbiology Workload: a Survey Study in Spain. Journal of Clinical Microbiology, 2007, 45, 2051-2053.	1.8	90
29	Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PLoS ONE, 2020, 15, e0237831.	1.1	85
30	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clinical Microbiology and Infection, 2020, 26, 1537-1544.	2.8	84
31	Antifungal stewardship in daily practice and health economic implications. Mycoses, 2015, 58, 14-25.	1.8	79
32	Spread of Carbapenem-Resistant Gram-Negatives and Candida auris during the COVID-19 Pandemic in Critically Ill Patients: One Step Back in Antimicrobial Stewardship?. Microorganisms, 2021, 9, 95.	1.6	77
33	Inhaled Liposomal Antimicrobial Delivery in Lung Infections. Drugs, 2020, 80, 1309-1318.	4.9	75
34	Is Azole Resistance in Aspergillus fumigatus a Problem in Spain?. Antimicrobial Agents and Chemotherapy, 2013, 57, 2815-2820.	1.4	73
35	DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci. Annals of Clinical Microbiology and Antimicrobials, 2019, 18, 30.	1.7	71
36	Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. Journal of Clinical Medicine, 2020, 9, 2780.	1.0	71

#	Article	IF	CITATIONS
37	The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis1. Transplantation, 2003, 75, 326-329.	0.5	69
38	Candida Infective Endocarditis: an Observational Cohort Study with a Focus on Therapy. Antimicrobial Agents and Chemotherapy, 2015, 59, 2365-2373.	1.4	68
39	Antifungal stewardship in a tertiary-care institution: a bedside intervention. Clinical Microbiology and Infection, 2015, 21, 492.e1-492.e9.	2.8	68
40	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics, 2020, 9, 71.	1.5	68
41	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	1.7	67
42	Infective Endocarditis in Patients With Bicuspid Aortic Valve or MitralÂValveÂProlapse. Journal of the American College of Cardiology, 2018, 71, 2731-2740.	1.2	65
43	Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant Klebsiella pneumoniae isolation: results of a double case–control study. Infection, 2013, 41, 61-67.	2.3	57
44	<i>Candida</i> biomarkers in patients with candidaemia and bacteraemia. Journal of Antimicrobial Chemotherapy, 2015, 70, 2354-2361.	1.3	55
45	Combination of <i>Candida</i> biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. Journal of Antimicrobial Chemotherapy, 2015, 70, 3107-3115.	1.3	55
46	New antibiotics for ventilator-associated pneumonia. Current Opinion in Infectious Diseases, 2018, 31, 177-186.	1.3	54
47	Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy. Journal of Nephrology, 2021, 34, 173-183.	0.9	52
48	Evaluation of MycAssayâ,,¢ Aspergillus for Diagnosis of Invasive Pulmonary Aspergillosis in Patients without Hematological Cancer. PLoS ONE, 2013, 8, e61545.	1.1	51
49	Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study. Intensive Care Medicine, 2017, 43, 509-518.	3.9	51
50	Candida auris Candidemia in Critically III, Colonized Patients: Cumulative Incidence and Risk Factors. Infectious Diseases and Therapy, 2022, 11, 1149-1160.	1.8	51
51	Molecular Epidemiological Investigation of a Nosocomial Cluster of C. auris: Evidence of Recent Emergence in Italy and Ease of Transmission during the COVID-19 Pandemic. Journal of Fungi (Basel,) Tj ETQq1	1 0. <b>7.8</b> 431	4 rg®T /Over
52	Lung regional stress and strain as a function of posture and ventilatory mode. Journal of Applied Physiology, 2011, 110, 1374-1383.	1.2	49
53	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). Open Forum Infectious Diseases, 2020, 7, ofaa139.	0.4	49
54	T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study. Journal of Antimicrobial Chemotherapy, 2018, 73, iv6-iv12.	1.3	47

#	Article	IF	CITATIONS
55	Targeted Antifungal Prophylaxis in Heart Transplant Recipients. Transplantation, 2013, 96, 664-669.	0.5	46
56	Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review. Infectious Diseases and Therapy, 2018, 7, 17-27.	1.8	46
57	Neurological Manifestations of Severe SARS-CoV-2 Infection: Potential Mechanisms and Implications of Individualized Mechanical Ventilation Settings. Frontiers in Neurology, 2020, 11, 845.	1.1	46
58	Isavuconazole shortens the QTc interval. Mycoses, 2018, 61, 256-260.	1.8	45
59	Invasive aspergillosis in the recipients of liver retransplantation. Liver Transplantation, 2006, 12, 1205-1209.	1.3	43
60	Chest physiotherapy: An important adjuvant in critically ill mechanically ventilated patients with COVID-19. Respiratory Physiology and Neurobiology, 2020, 282, 103529.	0.7	43
61	Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. Medical Mycology, 2014, 52, 270-275.	0.3	40
62	Antifungal Resistance to Fluconazole and Echinocandins Is Not Emerging in Yeast Isolates Causing Fungemia in a Spanish Tertiary Care Center. Antimicrobial Agents and Chemotherapy, 2014, 58, 4565-4572.	1.4	40
63	Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in highâ€risk liver transplantation recipients: A propensity score analysis. Liver Transplantation, 2016, 22, 427-435.	1.3	40
64	Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis—The ESCAPE Study. Clinical Infectious Diseases, 2018, 66, 825-832.	2.9	40
65	Lung nodular lesions in heart transplant recipients. Journal of Heart and Lung Transplantation, 2000, 19, 660-667.	0.3	39
66	The current treatment landscape: the need for antifungal stewardship programmes. Journal of Antimicrobial Chemotherapy, 2016, 71, ii5-ii12.	1.3	39
67	Rational approach in the management of Pseudomonas aeruginosa infections. Current Opinion in Infectious Diseases, 2018, 31, 578-586.	1.3	37
68	Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance. Antibiotics, 2020, 9, 632.	1.5	37
69	Retrospective case–control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. International Journal of Antimicrobial Agents, 2012, 39, 64-68.	1.1	36
70	Neurological Complications and Noninvasive Multimodal Neuromonitoring in Critically Ill Mechanically Ventilated COVID-19 Patients. Frontiers in Neurology, 2020, 11, 602114.	1.1	36
71	Invasive pulmonary aspergillosis in heart transplant recipients: Two radiologic patterns with a different prognosis. Journal of Heart and Lung Transplantation, 2014, 33, 1034-1040.	0.3	34
72	Invasive Candida Infections in Liver Transplant Recipients: Clinical Features and Risk Factors for Mortality. Transplantation Direct, 2017, 3, e156.	0.8	34

#	Article	IF	CITATIONS
73	Is routine ophthalmoscopy really necessary in candidemic patients?. PLoS ONE, 2017, 12, e0183485.	1.1	32
74	Coagulative Disorders in Critically III COVID-19 Patients with Acute Distress Respiratory Syndrome: A Critical Review. Journal of Clinical Medicine, 2021, 10, 140.	1.0	32
75	T2MR contributes to the very early diagnosis of complicated candidaemia. A prospective study. Journal of Antimicrobial Chemotherapy, 2018, 73, iv13-iv19.	1.3	31
76	Are incidence and epidemiology of anaerobic bacteremia really changing?. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1621-1629.	1.3	30
77	How much European prescribing physicians know about invasive fungal infections management?. BMC Infectious Diseases, 2015, 15, 80.	1.3	30
78	Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 95-104.	1.3	30
79	The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin. Clinical Microbiology and Infection, 2017, 23, 1000.e1-1000.e4.	2.8	29
80	Risk stratification for multidrug-resistant Gram-negative infections in ICU patients. Current Opinion in Infectious Diseases, 2019, 32, 626-637.	1.3	29
81	Endemic Genotypes of Candida albicans Causing Fungemia Are Frequent in the Hospital. Journal of Clinical Microbiology, 2013, 51, 2118-2123.	1.8	28
82	Regional distribution of lung compliance by image analysis of computed tomograms. Respiratory Physiology and Neurobiology, 2014, 201, 60-70.	0.7	28
83	Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa. Clinical Infectious Diseases, 2020, 71, 1799-1801.	2.9	28
84	The role of new β-lactamase inhibitors in gram-negative infections. Current Opinion in Infectious Diseases, 2019, 32, 638-646.	1.3	27
85	Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission. Journal of Fungi (Basel, Switzerland), 2022, 8, 305.	1.5	27
86	Universal Prophylaxis With Fluconazole for the Prevention of Early Invasive Fungal Infection in Low-Risk Liver Transplant Recipients. Transplantation, 2011, 92, 346-350.	0.5	26
87	Risk factors for late recurrent candidaemia. A retrospective matched case–control study. Clinical Microbiology and Infection, 2016, 22, 277.e11-277.e20.	2.8	26
88	Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. Medical Mycology, 2016, 54, 353-360.	0.3	25
89	Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clinical Microbiology and Infection, 2018, 24, 192-198.	2.8	25
90	Mould Infections of Traumatic Wounds: A Brief Narrative Review. Infectious Diseases and Therapy, 2020, 9, 1-15.	1.8	25

#	Article	IF	CITATIONS
91	Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?. Infectious Diseases and Therapy, 2020, 9, 137-149.	1.8	25
92	Therapeutic options for difficult-to-treat A <i>cinetobacter baumannii</i> infections: a 2020 perspective. Expert Opinion on Pharmacotherapy, 2021, 22, 167-177.	0.9	25
93	Poor compliance with antifungal drug use guidelines by transplant physicians: a framework for educational guidelines and an international consensus on patient safety. Clinical Transplantation, 2012, 26, 87-96.	0.8	24
94	Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant Staphylococcus epidermidis. Diagnostic Microbiology and Infectious Disease, 2013, 76, 99-102.	0.8	24
95	The current management landscape: aspergillosis: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71, ii23-ii29.	1.3	24
96	Usefulness of guideline recommendations for prognosis in patients with candidemia. Medical Mycology, 2019, 57, 659-667.	0.3	24
97	Diagnosis and Treatment of Candidemia in the Intensive Care Unit. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 524-539.	0.8	23
98	Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units. Critical Care, 2021, 25, 155.	2.5	23
99	Training should be the first step toward an antifungal stewardship program. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 221-227.	0.3	22
100	Candidemia in non-ICU surgical wards: Comparison with medical wards. PLoS ONE, 2017, 12, e0185339.	1.1	22
101	Efficacy of a "Checklist―Intervention Bundle on the Clinical Outcome of Patients with Candida Bloodstream Infections: A Quasi-Experimental Pre-Post Study. Infectious Diseases and Therapy, 2020, 9, 119-135.	1.8	22
102	No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins. Diagnostic Microbiology and Infectious Disease, 2017, 88, 141-144.	0.8	21
103	Challenges and research priorities to progress the impact of antimicrobial stewardship. Drugs in Context, 2019, 8, 1-15.	1.0	21
104	New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia. Seminars in Respiratory and Critical Care Medicine, 2022, 43, 280-294.	0.8	21
105	Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?. Diagnostic Microbiology and Infectious Disease, 2014, 80, 83-86.	0.8	20
106	Echinocandins Compared to Fluconazole for Candidemia of a Urinary Tract Source: A Propensity Score Analysis. Clinical Infectious Diseases, 2017, 64, 1374-1379.	2.9	19
107	Is biofilm production a prognostic marker in adults with candidaemia?. Clinical Microbiology and Infection, 2018, 24, 1010-1015.	2.8	19
108	Factors associated with the development of septic shock in patients with candidemia: a post hoc analysis from two prospective cohorts. Critical Care, 2020, 24, 117.	2.5	19

#	Article	IF	CITATIONS
109	Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions. Archives of Medical Research, 2021, 52, 817-827.	1.5	19
110	Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: Analysis of a 14-Month Prospective Clinical Experience. Journal of Chemotherapy, 2011, 23, 290-294.	0.7	18
111	Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 607-614.	1.3	18
112	Tracheostomy Timing and Outcome in Severe COVID-19: The WeanTrach Multicenter Study. Journal of Clinical Medicine, 2021, 10, 2651.	1.0	18
113	Frequency and clinical significance of bloodstream infections caused by C. albicans strains with reduced susceptibility to fluconazole. Diagnostic Microbiology and Infectious Disease, 2002, 44, 163-167.	0.8	17
114	Role of the Clinical Microbiology Laboratory in Antimicrobial Stewardship. Medical Clinics of North America, 2018, 102, 883-898.	1.1	17
115	Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. Infection, 2019, 47, 919-927.	2.3	17
116	An evidence-based bundle improves the quality of care and outcomes of patients with candidaemia. Journal of Antimicrobial Chemotherapy, 2020, 75, 730-737.	1.3	17
117	Treatment of severe infections due to metallo-β-lactamases-producing Gram-negative bacteria. Future Microbiology, 2020, 15, 1489-1505.	1.0	17
118	The Role of Dysbiosis in Critically III Patients With COVID-19 and Acute Respiratory Distress Syndrome. Frontiers in Medicine, 2021, 8, 671714.	1.2	17
119	Biomarkers of fungal infection: Expert opinion on the current situations. Revista Espanola De Quimioterapia, 2020, 33, 1-10.	0.5	17
120	Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardship. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1993-2000.	1.3	16
121	Methicillin-resistant Staphylococcus aureus lung infection in coronavirus disease 2019: how common?. Current Opinion in Infectious Diseases, 2022, 35, 149-162.	1.3	16
122	EPICO 3.0. Antifungal prophylaxis in solid organ transplant recipients. Revista Iberoamericana De Micologia, 2016, 33, 187-195.	0.4	15
123	The Role of Diagnostics-Driven Antifungal Stewardship in the Management of Invasive Fungal Infections: A Systematic Literature Review. Open Forum Infectious Diseases, 2022, 9, .	0.4	15
124	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. Transplant Infectious Disease, 2019, 21, e13195.	0.7	14
125	Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis. Mycoses, 2019, 62, 441-449.	1.8	14
126	COVID-19 associated infections in the ICU setting: A retrospective analysis in a tertiary-care hospital. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2023, 41, 278-283.	0.3	14

#	Article	IF	CITATIONS
127	Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. Infection and Drug Resistance, 2018, Volume 11, 479-488.	1.1	13
128	Clinical Relevance and Prognostic Value of Persistently Negative (1,3)-β-D-Glucan in Adults With Candidemia: A 5-year Experience in a Tertiary Hospital. Clinical Infectious Diseases, 2020, 70, 1925-1932.	2.9	13
129	Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates. Antimicrobial Agents and Chemotherapy, 2021, 65, e0124921.	1.4	13
130	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	1.8	13
131	Lung sound analysis correlates to injury and recruitment as identified by computed tomography: an experimental study. Intensive Care Medicine, 2011, 37, 1378-1383.	3.9	12
132	A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. Medical Mycology, 2020, 58, 300-309.	0.3	12
133	Early Effects of Passive Leg-Raising Test, Fluid Challenge, and Norepinephrine on Cerebral Autoregulation and Oxygenation in COVID-19 Critically III Patients. Frontiers in Neurology, 2021, 12, 674466.	1.1	12
134	Invasive aspergillosis in solid organ transplantation: Diagnostic challenges and differences in outcome in a Spanish national cohort (Diaspersot study). Mycoses, 2021, 64, 1334-1345.	1.8	12
135	Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad Trial and other new data. International Journal of Antimicrobial Agents, 2008, 32, S125-S131.	1.1	11
136	Bezlotoxumab for Preventing Recurrent Clostridioides difficile Infection: A Narrative Review from Pathophysiology to Clinical Studies. Infectious Diseases and Therapy, 2020, 9, 481-494.	1.8	11
137	Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study. Infectious Diseases and Therapy, 2021, 10, 387-398.	1.8	11
138	Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria. Expert Review of Anti-Infective Therapy, 2021, 19, 983-991.	2.0	11
139	Early Clinical Experience with Molnupiravir for Mild to Moderate Breakthrough COVID-19 among Fully Vaccinated Patients at Risk for Disease Progression. Vaccines, 2022, 10, 1141.	2.1	11
140	Invasive <i>Scedosporium</i> and <i>Lomentosora</i> infections in the era of antifungal prophylaxis: A 20â€year experience from a single centre in Spain. Mycoses, 2020, 63, 1195-1202.	1.8	10
141	Treatment of extended-spectrum β-lactamases infections: what is the current role of new β-lactams/β-lactamase inhibitors?. Current Opinion in Infectious Diseases, 2020, 33, 474-481.	1.3	10
142	<i>Aspergillus</i> â€PCR in bronchoalveolar lavage ―diagnostic accuracy for invasive pulmonary aspergillosis in critically ill patients. Mycoses, 2022, 65, 411-418.	1.8	10
143	Acoustic effects of positive end-expiratory pressure on normal lung sounds in mechanically ventilated pigs. Clinical Physiology and Functional Imaging, 2006, 26, 45-53.	0.5	9
144	Ceftaroline for severe community-acquired pneumonia: A real-world two-centre experience in Italy and Spain. International Journal of Antimicrobial Agents, 2020, 55, 105921.	1.1	9

#	Article	IF	CITATIONS
145	Role of new antibiotics in extended-spectrum β-lactamase-, AmpC- infections. Current Opinion in Infectious Diseases, 2021, Publish Ahead of Print, 748-755.	1.3	9
146	The role of new antimicrobials for Gram-negative infections in daily clinical practice. Current Opinion in Infectious Diseases, 2020, 33, 495-500.	1.3	9
147	Coxiella burnetii Infection in Hemodialysis and Other Vascular Grafts. Medicine (United States), 2014, 93, 364-371.	0.4	8
148	Higher Mortality and Intensive Care Unit Admissions in COVID-19 Patients with Liver Enzyme Elevations. Microorganisms, 2020, 8, 2010.	1.6	8
149	Infective endocarditis in patients with heart transplantation. International Journal of Cardiology, 2021, 328, 158-162.	0.8	8
150	Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care. European Journal of Internal Medicine, 2021, 94, 39-44.	1.0	8
151	Prognostic factors of Candida spp. bloodstream infection in adults: A nine-year retrospective cohort study across tertiary hospitals in Brazil and Spain. The Lancet Regional Health Americas, 2022, 6, 100117.	1.5	8
152	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.4	7
153	Utility of 1,3 β-d-Glucan Assay for Guidance in Antifungal Stewardship Programs for Oncologic Patients and Solid Organ Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2021, 7, 59.	1.5	7
154	Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications. Current Opinion in Infectious Diseases, 2021, 34, 96-108.	1.3	7
155	<i>Aspergillus</i> endocarditis in the recent years, report of cases of a multicentric national cohort and literature review. Mycoses, 2022, 65, 362-373.	1.8	7
156	Empirical treatment of candidemia in intensive care units: Fluconazole or broad-spectrum antifungal agents?. Medical Mycology, 2009, 47, 515-520.	0.3	6
157	New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Current Opinion in Infectious Diseases, 2021, 34, 701-709.	1.3	6
158	Early Administration of Bamlanivimab in Combination with Etesevimab Increases the Benefits of COVID-19 Treatment: Real-world Experience from the Liguria Region. Journal of Clinical Medicine, 2021, 10, 4682.	1.0	6
159	Potential role of new-generation antibiotics in acute bacterial skin and skin structure infections. Current Opinion in Infectious Diseases, 2021, 34, 109-117.	1.3	6
160	Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. Journal of Antimicrobial Chemotherapy, 2010, 65, 2266-2267.	1.3	5
161	Advances in the management of fungal infections. Mycoses, 2015, 58, 1-1.	1.8	5
162	T2 magnetic resonance for the diagnosis of deep-seated invasive candidiasis in a liver recipient without candidemia. Revista Iberoamericana De Micologia, 2018, 35, 159-161.	0.4	5

#	Article	IF	CITATIONS
163	Management of patients with septic shock due to <i>Candida</i> infection. Hospital Practice (1995), 2018, 46, 258-265.	0.5	5
164	Reply to: "Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19― Open Forum Infectious Diseases, 2020, 7, ofaa321.	0.4	5
165	Antibiotic treatment of acute bacterial skin and skin structure infections. Current Opinion in Infectious Diseases, 2022, 35, 120-127.	1.3	5
166	Fungaemia caused by rare yeasts: incidence, clinical characteristics and outcome over 10 years. Journal of Antimicrobial Chemotherapy, 2018, 73, 823-825.	1.3	4
167	T2Candida MR as a predictor of outcome in patients with suspected invasive candidiasis starting empirical antifungal treatment: a prospective pilot study—authors' response. Journal of Antimicrobial Chemotherapy, 2019, 74, 533-534.	1.3	4
168	High doses of hydroxychloroquine do not affect viral clearance in patients with SARS oVâ€2 infection. European Journal of Clinical Investigation, 2020, 50, e13358.	1.7	4
169	COVIDâ€19: Some clinical questions after the first 4Âmonths. European Journal of Clinical Investigation, 2020, 50, e13326.	1.7	4
170	Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Review of Respiratory Medicine, 2021, 15, 985-992.	1.0	4
171	Comparison of the Safety and Tolerance Profile of Micafungin with that of Other Echinocandins and Azoles in Patients with Pre-existing Child–Pugh B or C Liver Disease: A Case–Control Retrospective Study. Infectious Diseases and Therapy, 2020, 9, 151-163.	1.8	3
172	Disseminated lomentosporiosis in a heart transplant recipient: Case report and review of the literature. Transplant Infectious Disease, 2021, 23, e13574.	0.7	3
173	Improving management and antimicrobial stewardship for bacterial and fungal infections in hospitalized patients with COVID-19. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612210957.	1.1	3
174	Donor-derived invasive aspergillosis after kidney transplant. Medical Mycology Case Reports, 2018, 22, 24-26.	0.7	2
175	Adequate duration of therapy in severe fungal infections. Current Opinion in Critical Care, 2020, 26, 466-472.	1.6	2
176	Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections. Expert Opinion on Drug Safety, 2022, 21, 487-498.	1.0	2
177	Levels of beta-D-glucan in Candida auris supernatants, an inÂvitro and inÂvivo preliminary study. Clinical Microbiology and Infection, 2022, 28, 1154.e1-1154.e3.	2.8	2
178	Role of Antifungal Therapy in Complicated Intra-abdominal Infections. Current Infectious Disease Reports, 2020, 22, 1.	1.3	1
179	Neuro-toxoplasmosis and fatal necrotizing cerebellitis. Autopsy and Case Reports, 2022, 12, e2021363.	0.2	1
180	Antimicrobial Stewardship. Hematologic Malignancies, 2021, , 125-146.	0.2	0

#	Article	IF	CITATIONS
181	First Report of an Invasive Infection by Cephalotrichum gorgonifer in a Neutropenic Patient with Hematological Malignancy under Chemotherapy. Journal of Fungi (Basel, Switzerland), 2021, 7, 1089.	1.5	0